Crown Bioscience

🔔Join our essential webinar on biomarker discovery in oncology drug development! Our expert Dr. Rajendra Kumari will share insights on strategies to identify early biomarkers that reduce development risks and boost clinical success. You'll also get the opportunity to learn: ➡️How advanced models like organoids and PDX transform precision medicine. ➡️The role of multi-omics and in silico tools in translating complex datasets into actionable clinical insights. ➡️Tactics to address drug resistance and optimize combination therapies for personalized care. Don’t miss this opportunity to gain cutting-edge insights and refine your biomarker discovery strategies! Register now: https://hubs.la/Q02Zj9FC0

🧬 Choosing the right RNA analysis methods can be complex - but it doesn’t have to be! Our expert Yan Han breaks down three popular methods, helping you compare their features and understand when to use each. 🎧Prefer listening? Check out the audio version for insights on the go!

Read the new Crown Bioscience newsletter! 📰 Throughout November, we've proudly supported Lung Cancer Awareness Month. 🎗️ Our newsletter this month includes insights into lung cancer research along with our regular updates. 📺You can also watch our latest video about how we remove the guesswork for you! Follow us on LinkedIn to avoid missing our daily updates!

🦃 Happy Thanksgiving! As we pause to express gratitude on this special day, Crown Bioscience extends heartfelt thanks to our valued colleagues, clients, and partners. We are truly grateful for the trust you've placed in us, and we appreciate the opportunity to serve you. May this Thanksgiving bring joy, warmth, and cherished moments with loved ones.

We're heading to the Tumour Models London Summit! Meet our colleague Sarah Wagner, from 4th - 5th December to network and learn more about how to de-risk your studies with our services, including: ✅Our customized integrated solutions, with a comprehensive suite of resistance models across in vitro, in vivo, ex vivo, and in silico platforms, supported by a living biobank of over 30 cancer types. ✅Our ongoing R&D to expand our catalog, with custom model development to meet your research needs. ✅Integrating biomarker strategies, to help predict clinical responses, enabling the identification of translatable solutions Schedule a meeting in advance! https://hubs.la/Q02YWNvY0

Precision medicine aims to tailor treatment to individual patients based on their genetic, environmental, and lifestyle differences. Biomarker analysis plays a pivotal role in realizing this vision. Our latest blog post is your go-to guide for biomarker analysis and precision medicine, featuring: 📄Case Studies of Successful Biomarker-Driven Therapies 🧬Future Trends in Biomarker Analysis and Precision Medicine 🔎Frequently Asked Questions (FAQs) Learn how to stay ahead in the precision medicine revolution! ➡️ https://hubs.la/Q02YT28l0

Now available on-demand | This interactive session, hosted by Scientist.com and featuring experts from Crown Bioscience, covers topics such as best practices for tracking and managing licenses, legal frameworks and case studies on successful agreements. Gain practical knowledge on navigating licensing challenges, and learn how to protect your research from potential legal risks. View it now: https://lnkd.in/gHrEnjNd

Overcome challenges in translating preclinical cancer research into successful clinical outcomes with the help of our free White Paper: Decoding In Vitro Oncology Innovations: Organoids, OMICs, and Their Role in Early Cancer Drug Discovery. Discover how innovative 3D organoid models and integrated OMICs approaches can bridge the gap and improve the predictability of early-stage drug development. Here’s what you’ll gain: ✅Learn how organoids replicate patient-specific tumor environments, enhancing clinical relevance. ✅Explore the use of genomics, transcriptomics, and proteomics in developing predictive biomarkers. ✅See real-world applications that demonstrate how these technologies improve drug response prediction and patient stratification. Get your copy ➡️ https://hubs.la/Q02YT3z00

Are you looking to evaluate your NSCLC immunotherapies potential to overcome drug resistance? Crown Bioscience generated drug-resistant models of HCC827 via continuous exposure to specific EGFR TKIs and identified the mechanism of resistance in these models. These models have been subsequently used in preclinical development studies of new treatments for drug-resistant NSCLC cases. Download our free application note, detailing: ➡️The HCC827 validated cell line-derived xenograft (CDX) model, an adenocarcinoma cell line that contains patient-relevant activating EGFR mutation in exon 19 ➡️Generation of drug resistant HCC827 NSCLC CDX models for understanding mechanisms of resistance and testing new targeted treatments ➡️The HCC827 MiXeno™ model of transient human immunity and its utilization in the efficient evaluation of anti-PD-1 and anti-PD-L1 checkpoint inhibitor Learn more ➡️ https://hubs.la/Q02YT2hr0

OX40 is now at the forefront of what has been called “T cell co-stimulation”. Immune co-stimulators work by providing the signal that promotes the expansion and proliferation of killer CD8 and helper CD4 T cells. Our latest blog post gives you the full breakdown of the OX40 receptor and its binding partner, OX40-Ligand (OX40L), including: 🎯Targeting OX40 in preclinical studies: improved tumor free survival and immune memory response 🔀Treg cell effects – both depletion and expansion observed 🔬Clinical trials ongoing including combination therapy Learn more about OX40 Agonists ➡️https://hubs.la/Q02YT3ff0